Cellid Co., Ltd.

As of June 30, 2026, Cellid Co., Ltd. carries a market capitalization of 41.48B, placing it among publicly traded companies globally. Its enterprise value stands at 58.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Cellid Co., Ltd. has 29.50M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.98, and the price-to-book ratio stands at 0.77.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.60 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 58.33B versus a market cap of 41.48B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cellid Co., Ltd. maintains a current ratio of 0.57, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 62.86, indicating elevated leverage, while an interest coverage ratio of -19.50 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Cellid Co., Ltd. posted a negative return on equity (ROE) of -40.66, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -26.23, reflecting losses generated across the asset base. The company generates approximately 205.33M in revenue per employee across its workforce of 50.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.89 indicates how many times Cellid Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Cellid Co., Ltd.'s stock has declined approximately 40.62% over the past 52 weeks. The 50-day moving average sits at 2,271.12, while the 200-day moving average is 2,506.39.

Over the twelve months ended June 30, 2026, Cellid Co., Ltd. generated 10.42B in revenue and converted that into -27.38B in net income, yielding earnings per share of -928.27. EBITDA reached -8.30B, while operating income came in at -10.35B.

As of June 30, 2026, Cellid Co., Ltd. holds 16.90B in cash and equivalents against 33.74B in total debt, resulting in a net debt position of 20.65B. Total book value stands at 53.67B, with working capital of -15.23B providing operational flexibility.

Cellid Co., Ltd. produced -12.19B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -15.44B in capital expenditures, free cash flow totaled -27.63B - equivalent to -936.49 per share.

Over the twelve months ended June 30, 2026, Cellid Co., Ltd. posted a gross margin of 18.48, reflecting its pricing power and cost economics. The operating margin of -99.30 and net profit margin of -262.80 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -66.61: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -29.65, meaning Cellid Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Cellid Co., Ltd.'s most recent stock split took place on July 18, 2023 with a 298:327 split ratio.

As of June 30, 2026, Cellid Co., Ltd. has an Altman Z-Score of -1.60, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.